Leigh Ellis1,2, ShengYu Ku1,2, Qiuhui Li2, Gissou Azabdaftari1,3, Joseph Seliski4, Brian Olson4, Colleen S Netherby5, Dean G Tang2, Scott I Abrams5, David W Goodrich2, Roberto Pili6. 1. Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York. 2. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York. 3. Department of Pathology, Roswell Park Cancer Institute, Buffalo, New York. 4. University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. 5. Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York. 6. Department of Medicine, Indiana University-Simon Cancer Center, Indianapolis, Indiana.
Abstract
INTRODUCTION: Transgenic mouse modeling is a favorable tool to reflect human prostate tumorigenesis and interactions between prostate cancer and the microenvironment. The use of GEMMs and derived cell lines represent powerful tools to study prostate cancer initiation and progression with an associated tumor microenvironment. Notably, such models provide the capacity for rapid preclinical therapy studies including immune therapies for prostate cancer treatment. METHODS: Backcrossing FVB Hi-MYC mice with C57BL/6N mice, we established a Hi-MYC transgenic mouse model on a C57BL/6 background (B6MYC). In addition, using a conditional reprogramming method, a novel C57BL/6 MYC driven prostate adenocarcinoma cell line was generated. RESULTS: Our results demonstrate that disease progression is significantly delayed in B6MYC when compared to their FVB counterparts. Current data also indicates infiltrating immune cells are present in pre-cancer lesions, prostate intraepithelial neoplasia (PIN). Further, immunophenotyping of this immune infiltrate demonstrates the predominant population as myeloid-derived suppressor cells (MDSC). Also, we successfully generated a B6MYC-CaP cell line, and determined that this new PCa cell line express markers of luminal epithelial lineage. DISCUSSION: This novel model of PCa provides a new platform to understand the cross talk between MYC driven prostate cancer and the microenvironment. Importantly, these models will be an ideal tool to support the clinical development of immunotherapy as well as other novel therapeutic strategies for prostate cancer treatment. Prostate 76:1192-1202, 2016.
INTRODUCTION:Transgenicmouse modeling is a favorable tool to reflect human prostate tumorigenesis and interactions between prostate cancer and the microenvironment. The use of GEMMs and derived cell lines represent powerful tools to study prostate cancer initiation and progression with an associated tumor microenvironment. Notably, such models provide the capacity for rapid preclinical therapy studies including immune therapies for prostate cancer treatment. METHODS: Backcrossing FVB Hi-MYCmice with C57BL/6N mice, we established a Hi-MYCtransgenicmouse model on a C57BL/6 background (B6MYC). In addition, using a conditional reprogramming method, a novel C57BL/6 MYC driven prostate adenocarcinoma cell line was generated. RESULTS: Our results demonstrate that disease progression is significantly delayed in B6MYC when compared to their FVB counterparts. Current data also indicates infiltrating immune cells are present in pre-cancer lesions, prostate intraepithelial neoplasia (PIN). Further, immunophenotyping of this immune infiltrate demonstrates the predominant population as myeloid-derived suppressor cells (MDSC). Also, we successfully generated a B6MYC-CaP cell line, and determined that this new PCa cell line express markers of luminal epithelial lineage. DISCUSSION: This novel model of PCa provides a new platform to understand the cross talk between MYC driven prostate cancer and the microenvironment. Importantly, these models will be an ideal tool to support the clinical development of immunotherapy as well as other novel therapeutic strategies for prostate cancer treatment. Prostate 76:1192-1202, 2016.
Authors: Nrupen A Bhavsar; Jay H Bream; Alan K Meeker; Charles G Drake; Sarah B Peskoe; Djeneba Dabitao; Angelo M De Marzo; William B Isaacs; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08-22 Impact factor: 4.254
Authors: Zongxiang Zhou; Andrea Flesken-Nikitin; David C Corney; Wei Wang; David W Goodrich; Pradip Roy-Burman; Alexander Yu Nikitin Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: Cheryl M Koh; Charles J Bieberich; Chi V Dang; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo Journal: Genes Cancer Date: 2010-06
Authors: Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff Journal: Cancer Res Date: 2013-04-22 Impact factor: 12.701
Authors: Wouter R Karthaus; Phillip J Iaquinta; Jarno Drost; Ana Gracanin; Ruben van Boxtel; John Wongvipat; Catherine M Dowling; Dong Gao; Harry Begthel; Norman Sachs; Robert G J Vries; Edwin Cuppen; Yu Chen; Charles L Sawyers; Hans C Clevers Journal: Cell Date: 2014-09-04 Impact factor: 41.582
Authors: Trina J Stewart; David J Liewehr; Seth M Steinberg; Kristy M Greeneltch; Scott I Abrams Journal: J Immunol Date: 2009-07-01 Impact factor: 5.422
Authors: Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu Journal: Cancer Cell Date: 2003-09 Impact factor: 31.743
Authors: Ashley Orillion; Nur P Damayanti; Li Shen; Remi Adelaiye-Ogala; Hayley Affronti; May Elbanna; Sreenivasulu Chintala; Michael Ciesielski; Luigi Fontana; Chinghai Kao; Bennett D Elzey; Timothy L Ratliff; David E Nelson; Dominic Smiraglia; Scott I Abrams; Roberto Pili Journal: Clin Cancer Res Date: 2018-09-06 Impact factor: 12.531
Authors: Robert M Hughes; Brian W Simons; Hamda Khan; Rebecca Miller; Valentina Kugler; Samantha Torquato; Debebe Theodros; Michael C Haffner; Tamara Lotan; Jessie Huang; Elai Davicioni; Steven S An; Ryan C Riddle; Daniel L J Thorek; Isla P Garraway; Elana J Fertig; John T Isaacs; W Nathaniel Brennen; Ben H Park; Paula J Hurley Journal: Cancer Res Date: 2019-05-23 Impact factor: 12.701
Authors: Katherine L Morel; Anjali V Sheahan; Deborah L Burkhart; Sylvan C Baca; Nadia Boufaied; Yin Liu; Xintao Qiu; Israel Cañadas; Kevin Roehle; Max Heckler; Carla Calagua; Huihui Ye; Constantia Pantelidou; Phillip Galbo; Sukanya Panja; Antonina Mitrofanova; Scott Wilkinson; Nichelle C Whitlock; Shana Y Trostel; Anis A Hamid; Adam S Kibel; David A Barbie; Atish D Choudhury; Mark M Pomerantz; Christopher J Sweeney; Henry W Long; David J Einstein; Geoffrey I Shapiro; Stephanie K Dougan; Adam G Sowalsky; Housheng Hansen He; Matthew L Freedman; Steven P Balk; Massimo Loda; David P Labbé; Brian M Olson; Leigh Ellis Journal: Nat Cancer Date: 2021-03-22
Authors: Nancy Palechor-Ceron; Ewa Krawczyk; Aleksandra Dakic; Vera Simic; Hang Yuan; Jan Blancato; Weisheng Wang; Fleesie Hubbard; Yun-Ling Zheng; Hancai Dan; Scott Strome; Kevin Cullen; Bruce Davidson; John F Deeken; Sujata Choudhury; Peter H Ahn; Seema Agarwal; Xuexun Zhou; Richard Schlegel; Priscilla A Furth; Chong-Xian Pan; Xuefeng Liu Journal: Cells Date: 2019-10-27 Impact factor: 7.666